
May 10, 2026
Daiichi Sankyo Waiv Alliance Ties AI Pathology To ADC Valuation Story
Daiichi Sankyo has partnered with Waiv to integrate AI-driven digital pathology into its antibody-drug conjugate (ADC) program, focusing on biomarker discovery to enhance patient response predictions.This collaboration aims to leverage computational pathology to identify biomarkers that can indicate which patients are likely to benefit from specific ADC therapies. By enhancing the efficiency and precision of its oncology research, Daiichi Sankyo seeks to align its drug development more closely w









